NCT07132749View on ClinicalTrials.gov

NEPA in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXd

Not yet recruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions

Patients With HER2-positive Advanced Breast Cancer Treated With T-DXdPatients With HER2-low Advanced Breast Cancer Treated With T-DXd

Trial Locations (1)

06355

Samsung Medical Center, Seoul

Sponsors

Collaborators (1)

Helsinn Healthcare SA

All Listed Sponsors

collaborator

Helsinn Healthcare SA

INDUSTRY

lead

Yeon Hee Park

OTHER